Westra, Tjalke A <br/><br/>
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.  [electronic resource] 

 -  BMC infectious diseases  Feb 2013 
 - 75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2334 
<br/><br/><label>Standard No.: </label>10.1186/1471-2334-13-75  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Condylomata Acuminata--immunology<br/>Cost-Benefit Analysis<br/>Cross Protection<br/>Female<br/>Humans<br/>Mass Vaccination--economics<br/>Models, Economic<br/>Netherlands<br/>Papillomaviridae--classification<br/>Papillomavirus Vaccines--economics<br/>Quality-Adjusted Life Years<br/>Uterine Cervical Neoplasms--immunology